CAR T-Cell Immunotherapy Named Clinical Advance of the Year by ASCO
In January, ASCO published its 13th annual report in Clinical Cancer Advances 2018, and named chimeric antigen receptor (CAR) T-cell immunotherapy as its Advance of the Year. This repost highlights …
CAR T-Cell Immunotherapy Named Clinical Advance of the Year by ASCO Read More